Florida State University College of Medicine, Tallahassee, FL, U.S.A.
George Mason University, Fairfax, VA, U.S.A.
Anticancer Res. 2021 Feb;41(2):551-556. doi: 10.21873/anticanres.14807.
Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in the outcome of patients with metastatic prostate cancer who harbor certain genetic mutations. This concise review focuses on the 3 PARP inhibitors that have shown activity in metastatic prostate cancer.
在过去的十年中，转移性前列腺癌的治疗发生了重大变化。历史上，姑息治疗包括雄激素剥夺、化疗和不同的放射治疗方法。最近，聚 ADP-核糖聚合酶（PARP）抑制剂的突破性治疗导致了携带某些遗传突变的转移性前列腺癌患者的预后显著改善。这篇简明的综述重点介绍了在转移性前列腺癌中显示出活性的 3 种 PARP 抑制剂。
